Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

6.7%

4 terminated/withdrawn out of 60 trials

Success Rate

93.1%

+6.6% vs industry average

Late-Stage Pipeline

8%

5 trials in Phase 3/4

Results Transparency

13%

7 of 54 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 1
36(62.1%)
Phase 2
10(17.2%)
N/A
6(10.3%)
Phase 4
3(5.2%)
Phase 3
2(3.4%)
Early Phase 1
1(1.7%)
58Total
Phase 1(36)
Phase 2(10)
N/A(6)
Phase 4(3)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (60)

Showing 20 of 60 trials
NCT06087913Phase 1Completed

Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert

Role: collaborator

NCT06274398Phase 1Completed

Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study

Role: collaborator

NCT06897059Not ApplicableCompleted

Effectiveness of Smartphone Application for Adherence Support (Vuka+)

Role: collaborator

NCT04066881Phase 2Completed

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

Role: collaborator

NCT05458765Phase 2Completed

Project Engage: Oral PrEP Acceptability

Role: collaborator

NCT04047420Phase 1Completed

Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally

Role: collaborator

NCT04814927Phase 4Completed

Impact of Contraceptives on Cervico-Vaginal Mucosa

Role: collaborator

NCT01448616Phase 4Completed

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

Role: collaborator

NCT04195776Phase 1Completed

Evaluating Distribution of a Tenofovir Douche With Tap Water Douching and Simulated Receptive Anal Intercourse

Role: collaborator

NCT01768962Phase 1Completed

Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel

Role: lead

NCT01687205Phase 1Completed

Coital Pharmacokinetics/Pharmacodynamics (PK/PD) of Tenofovir Gel

Role: lead

NCT01232803Phase 1Completed

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

Role: lead

NCT01687218Phase 2Completed

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

Role: lead

NCT03762382Phase 2Unknown

Tenofovir/Levonorgestrel Intravaginal Ring and Tenofovir Intravaginal Ring

Role: lead

NCT01691768Phase 2Completed

Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services

Role: collaborator

NCT03279120Phase 1Completed

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

Role: lead

NCT03762772Phase 1Completed

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

Role: lead

NCT02602366Not ApplicableCompleted

The Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended Pregnancy

Role: lead

NCT00578877Phase 2Completed

Contraceptive Effectiveness and Safety of the SILCS Diaphragm

Role: lead

NCT02904369Phase 1Completed

PK and PD Study of Oral F/TAF for HIV Prevention

Role: lead